C059 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Background: The phase 3, randomized trial BRUIN CLL-321 assessed the safety and efficacy of pirtobrutinib vs investigators choice (IC) of idelalisib+rituximab (IdelaR) or bendamustine+rituximab (BR) in patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) pre-treated...

Descrizione completa

Dettagli Bibliografici

Autori principali:	P. Ghia, D. Rossi, E. Ferrant, F. De La Cruz Vicente, D. Maruyama, V. Banerji, P. Cobb, S. Namburi, R. Greil, A. Loubert, K. Creel, L.M. Hess, N. Payakachat, A.S. Ruppert, D. Wang, P. Abada, C.C. Leow, M. Hill, C.C. Coombs, P. Barr, J.P. Sharman
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Ferrata Storti Foundation 2025-09-01
Serie:	Haematologica
Accesso online:	https://haematologica.org/article/view/12823
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!